{"id":"l-v-tiracetam","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Somnolence"},{"rate":"10-15","effect":"Asthenia/fatigue"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Behavioral changes/mood changes"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levetiracetam is a pyrrolidone derivative that binds to the synaptic vesicle protein SV2A, which is involved in vesicle exocytosis and neurotransmitter release. This binding reduces the release of excitatory neurotransmitters and stabilizes neuronal membranes, preventing the spread of seizure activity. The exact mechanism remains incompletely understood, but SV2A binding is considered the primary molecular action responsible for its anticonvulsant effects.","oneSentence":"Levetiracetam reduces neuronal excitability by binding to synaptic vesicle protein SV2A, thereby modulating neurotransmitter release and preventing seizure propagation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:01.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive therapy for partial-onset seizures)"},{"name":"Epilepsy (adjunctive therapy for myoclonic seizures)"},{"name":"Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures)"}]},"trialDetails":[{"nctId":"NCT02631759","phase":"PHASE3","title":"Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-10","conditions":"Acute intraCerebral Haemorrhage","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6258,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lévétiracetam","genericName":"Lévétiracetam","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levetiracetam reduces neuronal excitability by binding to synaptic vesicle protein SV2A, thereby modulating neurotransmitter release and preventing seizure propagation. Used for Epilepsy (adjunctive therapy for partial-onset seizures), Epilepsy (adjunctive therapy for myoclonic seizures), Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}